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ABSTRACT
Introduction The simplest and cheapest method for 
cervical cancer screening is visual inspection after 
application of acetic acid (VIA). However, this method has 
limitations for correctly identifying precancerous cervical 
lesions (sensitivity) and women free from these lesions 
(specificity). We will assess alternative screening methods 
that could improve sensitivity and specificity in women 
living with humanimmunodeficiency virus (WLHIV) in 
Southern Africa.
Methods and analysis We will conduct a paired, 
prospective, screening test accuracy study among 
consecutive, eligible women aged 18–65 years receiving 
treatment for HIV/AIDS at Kanyama Hospital, Lusaka, 
Zambia. We will assess a portable magnification device 
(Gynocular, Gynius Plus AB, Sweden) based on the 
Swede score assessment of the cervix, test for high- risk 
subtypes of human papillomavirus (HR- HPV, GeneXpert, 
Cepheid, USA) and VIA. All study participants will receive 
all three tests and the reference standard at baseline 
and at six- month follow- up. The reference standard is 
histological assessment of two to four biopsies of the 
transformation zone. The primary histological endpoint 
is cervical intraepithelial neoplasia grade two and 
above (CIN2+). Women who are VIA- positive or have 
histologically confirmed CIN2+ lesions will be treated as 
per national guidelines. We plan to enrol 450 women. 
Primary outcome measures for test accuracy include 
sensitivity and specificity of each stand- alone test. In the 
secondary analyses, we will evaluate the combination 
of tests. Pre- planned additional studies include use of 
cervigrams to test an automated visual assessment 
tool using image pattern recognition, cost- analysis and 
associations with trichomoniasis.
Ethics and dissemination Ethical approval was obtained 
from the University of Zambia Biomedical Research Ethics 
Committee, Zambian National Health Regulatory Authority, 
Zambia Medicines Regulatory Authority, Swissethics and 
the International Agency for Research on Cancer Ethics 
Committee. Results of the study will be submitted for 
publication in a peer- reviewed journal.
Trial registration number NCT03931083; Pre- results.
INTRODUCTION
The risk of invasive cervical cancer is 
higher for women living with humanim-
munodeficiency virus (WLHIV) than for 
HIV- uninfected women.1–4 Cervical cancer 
remains the leading cause of death from 
cancer among women in Zambia, despite the 
introduction of an integrated service for HIV 
care and cervical screening in 2006.1 In 2020, 
human papillomavirus (HPV) vaccination was 
rolled out for adolescent girls in Zambia, but 
the effects on reducing the burden of cervical 
cancer will not be seen for at least 10 years.5 
Until then, secondary screening strategies 
are essential. Existing screening strategies 
in Southern Africa, so far, have not reduced 
the high burden of disease.1 5 The simplest 
and cheapest method for cervical cancer 
screening is visual inspection of the uterine 
Strengths and limitations of this study
 ► The study design allows evaluation of screening test 
accuracy of stand- alone and combinations of tests 
with adequate precision.
 ► This is the first study to assess the test accuracy of 
the Gynocular and validation of the Swede score as-
sessment of the cervix in women living with human 
immunodeficiencyvirus (WLHIV).
 ► All screened women will receive the reference stan-
dard of histological assessment at both baseline and 
follow- up, thereby reducing verification and mis-
classification bias.
 ► We will test an automated visual assessment tool, 
using a deep- learning algorithm in WLHIV.
 ► We limited the number of screening tests to be eval-
uated and excluded Papanicolaou testing, testing for 
DNA methylation, and human papillomavirus oncop-
roteins E6 and E7, as these were less suitable to 
implement in our study setting.
2 Taghavi K, et al. BMJ Open 2020;10:e037955. doi:10.1136/bmjopen-2020-037955
Open access 
cervix after application of 3%–5% acetic acid (VIA), 
and this method is employed widely in low- and middle- 
income countries (LMICs). When used as a stand- alone 
test, VIA has variable accuracy and high subjectivity.6 
Studies in sub- Saharan Africa have reported large varia-
tions in sensitivity of VIA when compared with histolog-
ical assessment: 25% (95% CI 7% to 59%) in Cameroon,7 
48% (95% CI 30% to 67%) in Zambia8 and 86.6% (95% 
CI 81.1% to 91.6%) in Kenya.9 The test accuracy of VIA is 
low when compared with the tests in screening pathways 
of high- income countries, which include Papanicolaou 
smear, testing for high- risk HPV (HR- HPV testing) and 
colposcopy, especially among WLHIV.6–12 Papanicolaou 
testing is hard to implement and scale- up in many coun-
tries, including Zambia, owing to shortages of patholo-
gists and high loss to follow- up.4
The World HealthOrganization (WHO) advocates for 
urgent investigation into the best methods of cervical 
cancer screening for WLHIV in LMICs,12 but a compre-
hensive evaluation of alternatives has not yet been 
performed. In sub- Saharan Africa, screening for precan-
cerous lesions of the cervix using HR- HPV testing has a 
sensitivity of 88.3% (95% CI 73.1% to 95.5%) and spec-
ificity of 73.9% (95% CI 50.7% to 88.7%).13 The WHO 
call for the elimination of cervical cancer has led to huge 
efforts to improve access to point- of- care HR- HPV testing 
in countries where this was previously too expensive to 
implement.6 14 It may soon be possible to roll out wide-
spread HR- HPV testing in many LMICs. However, the 
high prevalence of HR- HPV infection in WLHIV15 means 
that a screening strategy using HR- HPV alone may leave 
many women in need of treatment. This study provides 
an opportunity to assess the test accuracy of HR- HPV as 
a stand- alone test, and in combination with other tests, 
which might aid in treatment decisions.
We will investigate screening methods that could 
improve sensitivity and specificity for the detection of 
precancerous cervical lesions in WLHIV and could be 
scaled up in Zambia. We consider three strategies: Gynoc-
ular (Gynocular, Gynius Plus AB, Sweden), HR- HPV 
(GeneXpert, Cepheid, USA) and VIA, that adhere to the 
‘screen and treat’ principle. This is essential to ensure that 
screening is adequately linked to treatment and to mini-
mise loss to follow- up. In addition to VIA and HR- HPV 
testing, we will assess the Gynocular mobile magnifi-
cation device and Swede score of severity of cervical 
lesions. The Gynocular (figure 1) is battery- operated, 
allows inspection with a green light, has two brightness 
settings for the white light and has three magnification 
settings (5×, 8×, 12×), which allows magnified exam-
ination of the cervix, exceeding what is possible from 
low- magnification devices. Five published studies have 
examined the potential applications of the Gynocular in 
a general population.16–20 In clinical settings, the Gynoc-
ular is used with a validated scoring system for assessment 
of the cervix, the Swede score (the Swedish score), a tool 
to make colposcopic diagnosis less subjective.21 This study 
includes the first assessment of the Gynocular in WLHIV. 
The methods of the present study also allow the incorpo-
ration of substudies, including: (1) investigation of the 
accuracy of an automated visual assessment tool, using a 
deep- learning method for image recognition, outside of 
the clinical setting, which has shown potential in a study 
published in 201922; (2) a cost- analysis; and (3) a study 
of associations between Trichomonas vaginalis and vaginal 
and menstrual hygiene practices.23 24 The methods and 
statistical analysis plans for these studies will be described 
separately.
In this paper, we present the protocol for a clinical study 
to estimate test accuracy of Gynocular, HR- HPV and VIA 
in a stand- alone capacity, and in combination, in WLHIV 
in Lusaka, Zambia.
The primary objective is to:
1. Estimate the sensitivity and specificity of the Gynocular, 
HR- HPV and VIA when used as stand- alone tests to de-
tect cervical intraepithelial neoplasia, grade two and 
above (CIN2+) among WLHIV.
The secondary objectives are to:
1. Determine other measures of test accuracy of the 
Gynocular, HR- HPV testing and VIA.
2. Determine test accuracy for combinations of screening 
tests, that is, HR- HPV followed by Gynocular or VIA.
3. Investigate effects of patient characteristics on test ac-
curacy.
4. Determine optimal cut- offs for Swede score assessment 




This study received ethical approval and is reported 
in accordance with the 2015 ‘Standards for Reporting 
Diagnostic accuracy studies’ (STARD) guidelines. We 
present a single site, paired, prospective, screening test 
accuracy study in WLHIV in Lusaka, Zambia. All data 
collection is performed prospectively. Study data are 
recorded using paper and electronic Case Report Forms 
Figure 1 The Gynocular (Gynocular, Gynius Plus AB, 
Sweden). This photograph was taken at the Centre for 
Infectious Disease Research in Zambia headquarters on the 
27th of April 2020 for the purposes of this manuscript.
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(CRFs). A trained data associate enters data from paper 
CRFs into a password- protected electronic database 
(Research Electronic Data Capture, Vanderbilt Univer-
sity, Nashville, USA) once a week. This secure web appli-
cation managing online databases is monitored with the 
support of the Clinical Trials Unit at the University of 
Bern. All paper form entries and electronic form entries 
are verified.
Participants
The study population includes women enrolled in the 
antiretroviral therapy (ART) programme at Kanyama 
hospital in Lusaka, Zambia. In addition to ART services, 
the hospital has provided cervical screening since 
October 2006. The clinic has a well- established, VIA- based 
‘screen and treat’ approach to testing for precancerous 
cervical lesions. The main referral site for the study is the 
University Teaching Hospital, the tertiary level hospital in 
Lusaka, Zambia.
Patient enrolment occurs during the working hours 
of the ART clinic. A study research assistant gives a 
prescreening sensitisation talk to groups of women 
during their HIV clinic visits. The talk includes informa-
tion about the study requirements, as well as the benefits 
and risks of being involved. Women who are interested 
in participating then present themselves to the cervical 
screening clinic check- in desk, which is in a neighbouring 
building on the same hospital site. A study assistant deter-
mines eligibility. The study assistant explains the study 
in more detail and obtains written consent from eligible 
women in a private room. The consent form is available 
in two local languages (Nyanja and Bemba) and has been 
back translated into English to ensure accuracy. For illit-
erate study participants, a literate impartial witness is 
present during the entire consent process to ensure that 
all the relevant information has been provided and that 
the participant gives consent for participation voluntarily. 
These participants indicate their consent by placing 
their thumbprint on the consent form. Patients who do 
not wish to participate in this study continue to receive 
cervical cancer screening care and treatment according 
to the local standard of care. A maximum of four consec-
utive participants per day can be enrolled during clinic 
hours.
The inclusion criteria are:
1. Women attending the ART programme, with HIV in-
fection status confirmed from medical records.
2. Living within Kanyama district and intending to stay in 
the area for the next six months.
3. Age between 18 and 65 years.
4. Capacity and willingness to give consent.
5. Willingness to undergo a pelvic examination and cervi-
cal cancer screening.
6. Ever having had sexual intercourse.
7. Agreement to return for a follow- up appointment in 
6 months.
The exclusion criteria are:
1. A history of cervical cancer or hysterectomy where the 
cervix was also removed (previous treatment for pre-
cancerous lesions is permitted).
2. Pregnant or plans to become pregnant within 
six months of enrolment.
3. Having received vaccination against HPV.
To reduce the risk of selection bias, we do not exclude 
menstruating women but if blood obscures the view of the 
cervix through the speculum, we ask them to return for 
the examination after their menses. Enrolment started in 
May 2019. We plan to continue recruitment and follow- up 
until January 2021, but may need to amend these dates in 
response to the ongoing COVID-19 pandemic.
Test methods and study procedures
All consenting study participants complete a nurse- 
administered questionnaire by pen and paper, and 
undergo baseline testing for HIV RNA viral load, 
CD4 cell count and T. vaginalis. They also undergo all 
screening tests: HR- HPV testing, VIA screening and 
Gynocular assessment, in that sequence, during their first 
visit (figure 2). Two nurses and one research assistant 
are involved in data and specimen collection, and they 
perform their procedures in separate rooms. They record 
their results on separate report forms and are instructed 
not to communicate results together. The participants are 
also instructed not to communicate the findings of one 
nurse to another.
A clinic nurse first reviews the participants. She performs 
the first gynaecological examination and takes the spec-
imen for HR- HPV testing, followed by the specimen for T. 
vaginalis testing, and then performs a VIA examination. 
The HR- HPV testing is done using a single- use cervical 
cytobrush provided by GeneXpert. The cytobrush spec-
imen is placed into ThinPrep PreservCyt (Cepheid, 
Sunnyvale, California, USA) immediately after collec-
tion. The T. vaginalis test is taken using a cotton- tipped 
swab provided by GeneXpert. These samples are passed 
on to a research assistant, before commencement of the 
VIA examination. The specimens are processed at the 
same time by the GeneXpert machine (Cepheid, Sunny-
vale, California, USA), according to the manufacturer’s 
instructions. The machine is located in the cervical cancer 
screening clinic. HPV testing output is then categorised 
into negative, positive HPV 16, positive HPV 18 or 45, or 
positive for other HR- HPV, including the following HPV 
subtypes: 11, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66 and 68.
VIA is carried out using the methodology described 
by the International Agency for Research on Cancer 
(IARC).24 This is summarised as follows: insertion of a 
speculum, followed by visualisation of the vagina, vulva 
and cervix; assessment with the naked eye after appli-
cation of normal saline and further assessment after 
application of 5% acetic acid for one minute. The nurse 
records the findings as normal, abnormal or suspicious of 
cancer. Local guidelines instruct VIA nurses to categorise 
indeterminate findings as abnormal.
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A different nurse performs the Gynocular exam-
ination, after VIA, in a different examination room, 
following the steps for colposcopy as described in the 
IARC colposcopy manual.24 These steps include inser-
tion of a speculum followed by visualisation of the vagina, 
vulva and cervix, assessment of the cervix at low and high 
magnification (>6×) after application of normal saline, 
examination of cervical vessel patterns using the red- free 
mode (or green filter), application of 5% acetic acid for 
one minute, and finally assessment following application 
with Lugol’s iodine. The findings of the examination are 
documented using the Swede score to standardise the 
assessment of cervical lesions.20 25 The Swede score uses 
five domains (vessels, margins or surface, acetic acid 
uptake, iodine staining and lesion size). Each domain 
is scored between zero and two, based on the severity 
of the findings, and summed to a total score between 
zero (best) and ten (worst).26 The test positivity cut- offs 
Figure 2 Flow of participants through the study*. VIA- positive women and those who have CIN2+ on histopathology will be 
treated as per national guidelines. Numbers of participants at each step will be reported. Loss to follow- up and missing data 
will also be reported. *This flow diagram is in accordance with the 2015 ‘Standards for Reporting Diagnostic accuracy studies’. 
ART, antiretroviral therapy; CD4, cluster of differentiation 4; CIN2+, cervical intraepithelial neoplasia grade two and above; HR- 
HPV, high- risk human papillomavirus; TZ, transformation zone of the cervix; VIA, visual inspection of the uterine cervix after 
application of 3%–5% acetic.
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are not predefined in WLHIV and will be determined by 
our results. We did not train nurses to use endocervical 
forceps or perform endocervical curettage in the pres-
ence of a type 3 transformation zone, since the guide-
lines of the Zambian Ministry of Health do not allow 
nurses to perform these procedures. Women who are 
considered ineligible for treatment due to type 2 or type 
3 transformation zone will be referred to a local gynae-
cologist for management.
The second study nurse takes cervical images using 
the smartphone attached to Gynocular at each stage of 
the examination. The images are stored electronically 
on a hard- drive and a secure server at Centre for Infec-
tious Disease Research in Zambia (CIDRZ) headquarters. 
In a separate study, we will use coded images linked to 
anonymised clinical data obtained in the study, to test 
an automated visual assessment tool using deep- learning 
methods for image pattern recognition for the detection 
of CIN2+ lesions of the cervix.
The reference standard is the histological assessment of 
cervical tissue biopsies. All participants receive between 
two and four biopsies. At least two biopsies are obtained 
from women who have visible lesions. If no lesion is seen, 
four biopsies are obtained from clock- face positions of 
12, 3, 6 and 9 o’clock within the transformation zone. All 
biopsies are taken perpendicular to the epithelium, are 
deep enough to sample the entire epithelium along with 
a small amount of stroma and are placed in formalin. To 
ensure standardisation, a study nurse received training 
in colposcopy and biopsy taking from a gynaecologist at 
IARC and a senior local gynaecologist.
All biopsies are sent for processing and examination 
at a laboratory in South Africa. An expert gynaecolog-
ical pathologist, blinded to the visual assessment, will 
examine the biopsies. Slides are classified using the 
cervical intraepithelial neoplasia (CIN) classification 
system. CIN1 affects only the lower third of the epithe-
lium (mild dysplasia), CIN2 involves two- thirds of the 
epithelium and CIN3 involves the full thickness (severe 
dysplasia and carcinoma in situ). These findings are then 
dichotomised into low- grade and high- grade squamous 
intraepithelial lesions (HSIL), by the Lower Anogenital 
Squamous Terminology definitions. All histology with 
CIN2 that stained diffusely positive for p16 is considered 
as HSIL, and all patients with CIN3 are considered as 
HSIL. Management decisions during the study will be 
based on the histological assessments done at this labo-
ratory. At the conclusion of the study, an independent 
pathologist will verify all histopathology results, and we 
will use a consensus assessment for academic purposes in 
our analysis of outcomes.
The primary histological endpoint for our study is 
CIN2+. However, we will also determine the histological 
endpoint of HISL based on p16. To ascertain the pres-
ence of true high- grade cervical disease, we will rely 
on biopsy findings at baseline and 6- month follow- up. 
Disease detected at 6 months will be considered a missed 
case rather than a new case, because CIN progression is 
slow it is unlikely that a woman developed a new case in 
so short a time.
Women with VIA- positive findings are eligible for 
ablative treatment at their baseline visit, as per national 
guidelines. Treatment by cryotherapy or thermoablation 
is administered if the lesion fulfils the following criteria: 
boundaries are fully visible, covers less than 75% of the 
ectocervix, does not extend into the endocervical canal 
or the vagina, and is fully covered using the cryotherapy 
tip being used.25 VIA- positive women who are not eligible 
for immediate ablative treatment, and women who are 
assessed to have lesions suspicious of cancer, are referred 
immediately to the University Teaching Hospital or 
another nearby facility which offers the required treat-
ment. All women with CIN2+ on histopathology and 
missed treatment at baseline (VIA- negative findings) will 
be offered treatment as per national guidelines.
The clinical pathway allows blinding of index tests and 
the reference standard for the clinical team performing 
tests. The clinic nurse performs VIA assessment and 
baseline tests first in a designated examination room. 
The participant then presents to a different examination 
room, where the second study nurse repeats the spec-
ulum examination and performs the Gynocular exam-
ination. To preserve blinding of the study nurse to VIA 
findings, the clinic nurse treats women with VIA- positive 
findings amenable to cryotherapy after completion of all 
other study procedures. She instructs the participant not 
to communicate this plan to the study nurse performing 
the Gynocular examination. Women with positive biopsy 
results receive treatment at a planned follow- up visit (‘visit 
2’). All women are followed up at 6 months (‘visit 3’), 
during which the study participants undergo the same 
tests (HR- HPV, VIA, Gynocular and a biopsy).
Different assessors independently perform VIA (clinic 
nurse), HR- HPV testing (first study nurse) and Gynoc-
ular (second study nurse) examinations, and record 
results on separate data collection forms. GeneXpert 
HR- HPV testing follows the physical examinations; the 
result cannot influence the VIA nurse or Gynocular nurse 
assessments as it is only available after all visual examina-
tions are complete. Biopsy results are known only after 
the completion of VIA, HR- HPV and Gynocular tests.
Sample size calculation and analysis
This screening test accuracy study requires 350 partici-
pants to estimate the sensitivity and specificity of Gynoc-
ular, HR- HPV and VIA for CIN2+ lesions with the precision 
detailed in table 1. Screening accuracy measures will be 
estimated with 95% Wilson confidence intervals with no 
formal hypothesis testing between modalities.
We will enrol 450 women to obtain data from at least 
350 patients for statistical analyses. We expect the preva-
lence of CIN2+ in WLHIV in Zambia to be 16%–20%.8 27 28 
We expect disease prevalence to be lower than in previous 
years. Increases in the number of women receiving ART, 
and commencing treatment at higher CD4 cell counts,29 
may lead to a decline in HPV prevalence.30 Higher rates 
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of voluntary male circumcision in male partners may also 
contribute to lower levels of HPV infection.30 We also esti-
mate that there might be up to 10% loss to follow- up and 
up to 10% of tests that are not analysable or interpretable. 
We have implemented rigorous data collection methods 
to avoid missing data, such as patient demographics, clin-
ical history and test results.
A complete list of outcomes can be found in our clin-
ical trials registration and in the online supplemental 
material 1.
Primary outcomes are:
1. The sensitivity and specificity of the Gynocular, HR- 
HPV and VIA when used as stand- alone tests to detect 
CIN2+ among WLHIV.
Secondary outcomes are:
1. Other test accuracy measures of the Gynocular, HR- 
HPV testing and VIA which include positive and nega-
tive predictive values, positive and negative likelihood 
ratios, false- positive rate, false- negative rate, number 
needed to screen, and area under the receiver oper-
ating characteristic (ROC) curve and the diagnostic 
ORs.
2. Estimates of accuracy for tests when they are done in 
sequence. For example, HR- HPV positive test followed 
by Gynocular, and HR- HPV positive test followed by 
VIA.
3. Estimates of test accuracy in subgroups defined by age, 
menopausal status, parity, education, ART status, CD4 
cell count, HIV RNA viral load, coinfection with T. 
vaginalis, methods of contraception, and earlier treat-
ment for precancer and potential effect modification. 
The specific categorisation of the variables in the sub-
group analysis is defined in the online supplemental 
material 2.
4. Area under the ROC curve for the Swede score deter-
mined by Gynocular.
A detailed statistical analysis plan has been drafted as 
a separate document, to describe planned analyses for 
the predefined outcomes and planned subgroup anal-
yses. This can be found as an attachment to our clinical 
trials registration. In summary, two- by- two tables will be 
created to calculate sensitivity and specificity, positive 
and negative predictive values, positive and negative 
likelihood ratios, false- positive rate, false- negative rate, 
diagnostic odds ratio, and number needed to screen. 
Test accuracies will be calculated for each test in a 
stand- alone and add- on capacity, with corresponding 
confidence intervals using the Wilson score method.31 
Area under the ROC curve for the Swede score as deter-
mined by the Gynocular will also be calculated. We will 
also evaluate test accuracy in subgroups defined by age, 
menopausal status, parity, education, ART status, CD4 
cell count, HIV RNA viral load, coinfection with T. vagi-
nalis, methods of contraception and earlier treatment 
for precancer. We will use logistic regression models 
to assess whether these patient characteristics have an 
influence on the association between each diagnostic 
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Indeterminate results from the index test or reference 
standard will be reported, and sensitivity analysis will be 
performed to quantify the possible range of accuracy if 
participants with an indeterminate test or reference stan-
dard data are classified as positive or negative. The distri-
bution of baseline characteristics between the participants 
with missing data and those without will be compared and 
managed similarly, with a sensitivity analysis to quantify 
the possible range of accuracy if participants with missing 
data are classified as diseased or non- diseased. If the 
missing data can be categorised as missing at random, 
such as lost samples, technical failures or accidental devia-
tions from the protocol, multiple imputation may be used 
to reconstruct the data.
Safety monitoring
An independent Data Safety and Monitoring Board has 
been selected to safeguard the interests of study partic-
ipants and advise principal investigators (PIs) on study 
validity and integrity.
DISCUSSION
The limitations of VIA for screening WLHIV have been 
widely noted, and the WHO acknowledges the need for 
improved screening strategies.32 HR- HPV testing is being 
promoted; however, in settings where it is not available, 
VIA is preferred over no screening.28 32 In order to mini-
mise loss to follow- up, same day screening and treatment 
is also recommended in many countries. Some HPV 
testing platforms have the capacity to process samples 
quickly and provide results after 60 min, making a ‘screen 
and treat’ approach possible. We use an HPV testing plat-
form that has been shortlisted by the WHO to run in this 
capacity.33 Our study fills an important evidence gap by 
exploring new strategies for the detection of precancerous 
cervical lesions in WLHIV in LMICs. Deriving estimates of 
test accuracy for all three tests in the same study popu-
lation reduces bias and strengthens the internal validity 
of the study. Although studies show that HPV is more 
sensitive than VIA, specificity is relatively low, especially in 
WLHIV.34–36 Therefore, our study design allows the assess-
ment of tests in both a stand- alone and add- on capacity. 
We also take measures to minimise two important forms 
of bias that compromise similar studies, including verifi-
cation bias and misclassification bias.
Identifying true disease depends on the accurate place-
ment of biopsies. A true gold standard would be to obtain 
a large loop excision of the transformation zone of every 
enrolled woman, but this approach would be unethical 
due to the complications of this procedure for women 
of childbearing age.37 In order to reduce misclassifica-
tion, we use histopathology results of multiple punch 
biopsies obtained from the cervix, as the ‘reference 
standard’. Several studies show that obtaining multiple 
biopsies improves detection of CIN2+ lesions compared 
with the practice of one biopsy from the most severe 
cervical lesion. Wentzensen et al found that sensitivities 
for detecting CIN2+ increased from 61% (95% CI 55% to 
67%) in a single biopsy, to 86% (95% CI 80% to 90%) with 
two biopsies, and 96% (95% CI 91% to 99%) with three 
biopsies.38 This was verified by the same research group39 
and supported by other research groups in Asia and 
Europe.40–44 In addition, taking biopsies in the absence 
of abnormal colposcopic findings increases detection of 
high- grade lesions.35 40 42–46 Many studies on colposcopic 
techniques include the use of multiple biopsies, even 
when lesions are not seen.8 16 38 39 42 44–52 In our study, all 
acetowhite lesions are biopsied. When no lesion is seen, 
one biopsy is taken from each quadrant within the trans-
formation zone. Furthermore, true disease is defined as 
the sum of all positive lesions identified at two close time 
points (baseline and 6 months), to ensure any lesions 
missed at baseline can be included. We chose a short 
follow- up period so we could identify CIN2+ cases that 
were missed at baseline. We expect this follow- up will pick 
up missed cases from baseline instead of progression or 
new cases. This may allow us to estimate true disease more 
accurately, but such a short follow- up cannot reliably be 
used to identify progression or new disease. However, this 
is not the objective of our study. We will include women 
who may have sexually transmitted infections (STIs), as 
this situation occurs in real life. Trichomoniasis is the 
most common STI in this setting. Because the inflamma-
tion caused by T. vaginalis may affect visual assessment of 
the cervix, we will assess test accuracy in women with and 
without coinfection, using GeneXpert for sensitive and 
specific detection of T. vaginalis. A limitation of this work 
is the small number of screening tests being evaluated. 
Other screening tests, including Papanicolaou testing, 
testing for DNA methylation and HPV oncoproteins E6 
and E7, were considered, but these are more difficult to 
implement in our study setting.
To meet the 2030 WHO targets for the elimination of 
cervical cancer, new strategies are required to address 
pervasive problems in LMICs, such as transport for 
patients to hospitals and clinics, a lack of gynaecologists 
and other trained healthcare workers, and access to labo-
ratory equipment. Urgent investigation into the best 
methods of screening for WLHIV are required, and we 
present a study investigating relevant tests that could be 
employed in screen and treat settings using methods to 
minimise bias. The results from this work may be useful 
in informing future screening guidelines for WLHIV in 
sub- Saharan Africa.
Patient and public involvement
Patients and members of the public were not involved in 
the design of this study. We invite verbal or written feed-
back from participants throughout the running of the 
study by facilitating direct communication study nurses 
or the site- principal investigator as required.
Dissemination
Results will be shared with patients and stakeholders. 
We will disseminate the findings of this study using a 
8 Taghavi K, et al. BMJ Open 2020;10:e037955. doi:10.1136/bmjopen-2020-037955
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range of methods, including the use of academic media 
(peer- reviewed journal articles, national and interna-
tional conference presentations), electronic and postal 
mail (posting of study findings to participants), commu-
nity and stakeholder engagement activities (including 
provision of findings to the Cervical Cancer Prevention 
Programme and Ministry of Health in Zambia) and social 
media.
Ethics
This study received ethical approval from: National 
Health Research Authority and the University of Zambia 
Biomedical Research Ethics Committee (ref: 014-09-
18), the Zambia Medicines Regulatory Authority (ref: 
DMS/7/9/22/CT/084), the International Agency for 
Research on Cancer (IEC project number 18-15) and 
Swissethics (ref: 2018-01399). The protocol follows the 
2015 STARD guidelines, as will the subsequent report of 
findings.
Protocol and data availability
The protocol, as approved by the respective ethical 
committees, is available on request to the corresponding 
author of this manuscript. Anonymised study data will be 
stored for ten years. We plan to publish results in open 
access journals with data available in accordance with 
‘FAIR principles’.
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